Regulators, the public, and the medical community are scrutinizing the safety profiles of pharmaceuticals more closely than ever. Thus acquiring, verifying and reporting quality safety data are crucial to obtaining and maintaining product approval. This course introduces fundamental concepts essential to drug safety and adverse event reporting and how to apply them to situations encountered during clinical trials and post-marketing reporting. You'll learn why safety reporting is crucial; the definitions of an adverse event and the key reporting issues of seriousness, expectedness, and relationship to the study drug. The course includes a brief overview of reporting requirements in the U.S. and abroad and the documents associated with these reports. The content is appropriate for CRAs, CRCs, drug safety associates, and regulatory affairs personnel.
黑料不打烊 EXTENSION Approved by the California Board of Registered Nursing, Provider Number 13114, for 15 contact hours
This class meets simultaneously in a classroom and remotely via Zoom. Students are expected to attend and participate in the course, either in-person or remotely, during the days and times that are specified on the course schedule. Students attending remotely are also strongly encouraged to have their cameras on to get the most out of the remote learning experience. Students attending the class in-person are expected to bring a laptop to each class meeting.
To see all meeting dates, click “Full Schedule” below.
You will be granted access in Canvas to your course site and course materials approximately 24 hours prior to the published start date of the course.
